These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 16414494)

  • 21. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.
    Al Otaibi M; Ross P; Fahmy N; Jeyaganth S; Trottier H; Sircar K; Bégin LR; Souhami L; Kassouf W; Aprikian A; Tanguay S
    Cancer; 2008 Jul; 113(2):286-92. PubMed ID: 18484590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
    BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
    Abouassaly R; Lane BR; Jones JS
    Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling prostate specific antigen kinetics in patients on active surveillance.
    Zhang L; Loblaw A; Klotz L
    J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
    Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
    Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
    Klotz L; Zhang L; Lam A; Nam R; Mamedov A; Loblaw A
    J Clin Oncol; 2010 Jan; 28(1):126-31. PubMed ID: 19917860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].
    Kawa G; Hiura Y; Satoh H; Sugi M; Fujita I; Oguchi N; Doi H; Ashida M; Okada H; Muguruma K; Murota T; Koyama Y; Kawamura H; Ohara T; Kawakita M; Matsuda T
    Hinyokika Kiyo; 2002 Mar; 48(3):133-8. PubMed ID: 11993205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An analysis of men with clinically localized prostate cancer who deferred definitive therapy.
    Patel MI; DeConcini DT; Lopez-Corona E; Ohori M; Wheeler T; Scardino PT
    J Urol; 2004 Apr; 171(4):1520-4. PubMed ID: 15017211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.